{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:41:45Z","timestamp":1777455705177,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001786","name":"University of Adelaide","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jgar.2020.10.017","type":"journal-article","created":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T17:24:13Z","timestamp":1605461053000},"page":"388-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia"],"prefix":"10.1016","volume":"23","author":[{"given":"Shio-Shin","family":"Jean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Wen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.10.017_bib0005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10096-009-0866-6","article-title":"In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: nationwide data from the SMART programme","volume":"29","author":"Jean","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.10.017_bib0010","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/jac\/dku114","article-title":"Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective","volume":"69","author":"Alm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jmii.2018.11.004","article-title":"Recommendations and guidelines for the treatment of pneumonia in Taiwan","volume":"52","author":"Chou","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2020.10.017_bib0020","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jmii.2019.01.001","article-title":"Distribution of virulence genes in bacteremic methicillin-resistant Staphylococcus aureus isolates from various sources","volume":"52","author":"Wang","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2020.10.017_bib0025","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jmii.2018.06.007","article-title":"Comparison of clinical characteristics of bacteremia from Elizabethkingia meningoseptica and other carbapenem-resistant, non-fermenting Gram-negative bacilli at a tertiary medical center","volume":"52","author":"Huang","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2020.10.017_bib0030","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1469-0691.2006.01377.x","article-title":"Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values","volume":"12","author":"Turnidge","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2020.10.017_bib0035","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1128\/AAC.00078-09","article-title":"In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates","volume":"53","author":"Adam","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0040","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/jac\/dkp370","article-title":"In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan","volume":"64","author":"Chen","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0045","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1089\/mdr.2016.0021","article-title":"In vitro resistance development to nemonoxacin in Streptococcus pneumoniae: a unique profile for a novel nonfluorinated quinolone","volume":"22","author":"Roychoudhury","year":"2016","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2020.10.017_bib0050","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/mdr.2019.0048","article-title":"Selected mutations by nemonoxacin and fluoroquinolone exposure among relevant Gram-positive bacterial strains in Taiwan","volume":"26","author":"Yang","year":"2020","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2020.10.017_bib0055","series-title":"Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI Supplement M100","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.jgar.2020.10.017_bib0060","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1469-0691.2009.02951.x","article-title":"Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan","volume":"16","author":"Hsieh","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2020.10.017_bib0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/AAC.00682-09","article-title":"Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers","volume":"54","author":"Lin","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0070","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1128\/AAC.04039-14","article-title":"Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers","volume":"59","author":"Wu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0075","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/11632780-000000000-00000","article-title":"Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses","volume":"32","author":"Guo","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jgar.2020.10.017_bib0080","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0085","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/AAC.01098-12","article-title":"Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model","volume":"57","author":"Liang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jgar.2019.10.004","volume":"21","author":"Jean","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2020.10.017_bib0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jmii.2017.07.011","article-title":"Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, noninferiority trial","volume":"52","author":"Yuan","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2020.10.017_bib0100","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/AAC.01197-09","article-title":"Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates","volume":"54","author":"Lauderdale","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0105","series-title":"49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Activity of nemonoxacin, an investigational C8-methoxy non-fluorinated quinolone, against pathogens isolated from Canadian hospitals: CANWARD 2007\u20132008","author":"Laing","year":"2009"},{"key":"10.1016\/j.jgar.2020.10.017_bib0110","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Infectious Diseases Society of America (IDSA) Joint Conference","article-title":"Comparative antistaphylococcal activity of nemonoxacin, a novel broad-spectrum quinolone","author":"Pankuch","year":"2008"},{"key":"10.1016\/j.jgar.2020.10.017_bib0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2020.10.017_bib0120","unstructured":"The epidemiological cutoff values of antibiotics in China [in Chinese]. https:\/\/mp.weixin.qq.com\/s\/B20bneZBNVGwYyknIEOr8A [Accessed 19 July 2020]."},{"key":"10.1016\/j.jgar.2020.10.017_bib0125","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1128\/JCM.02416-16","article-title":"Establishment and use of epidemiological cutoff values for molds and yeasts by use of the Clinical and Laboratory Standards Institute M57 standard","volume":"55","author":"Lockhart","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2020.10.017_bib0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/dkg312","article-title":"European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria","volume":"52","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0135","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1128\/AAC.00295-10","article-title":"Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia","volume":"54","author":"van Rensburg","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.10.017_bib0140","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jmii.2018.11.006","article-title":"Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia","volume":"52","author":"Cheng","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2020.10.017_bib0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/IDR.S193233","article-title":"The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials","volume":"12","author":"Chang","year":"2019","journal-title":"Infect Drug Resist"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520302800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520302800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:53:43Z","timestamp":1761990823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520302800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"alternative-id":["S2213716520302800"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.10.017","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}